Grifols, S.A. (NASDAQ:GRFS) Receives Average Recommendation of “Hold” from Analysts

Grifols, S.A. (NASDAQ:GRFS) has received an average rating of “Hold” from the five research firms that are covering the stock, MarketBeat Ratings reports. Four equities research analysts have rated the stock with a hold recommendation and one has assigned a buy recommendation to the company. The average twelve-month price objective among analysts that have issued ratings on the stock in the last year is $10.30.

GRFS has been the subject of a number of research analyst reports. Weiss Ratings restated a “hold (c)” rating on shares of Grifols in a report on Wednesday, October 8th. Zacks Research raised Grifols to a “hold” rating in a research report on Friday, August 8th. Wall Street Zen lowered Grifols from a “strong-buy” rating to a “buy” rating in a research report on Saturday, October 11th. Finally, Deutsche Bank Aktiengesellschaft reissued a “hold” rating on shares of Grifols in a report on Tuesday, August 5th.

Grifols Stock Performance

Shares of Grifols stock opened at $9.36 on Wednesday. The business has a 50-day moving average of $9.76 and a 200 day moving average of $9.12. Grifols has a 12 month low of $6.19 and a 12 month high of $11.14. The stock has a market capitalization of $6.44 billion, a price-to-earnings ratio of 44.57, a price-to-earnings-growth ratio of 0.32 and a beta of 0.69. The company has a debt-to-equity ratio of 1.20, a current ratio of 2.64 and a quick ratio of 0.95.

Institutional Trading of Grifols

A number of institutional investors have recently modified their holdings of GRFS. Sequoia Financial Advisors LLC boosted its position in Grifols by 14.9% during the first quarter. Sequoia Financial Advisors LLC now owns 26,230 shares of the biotechnology company’s stock worth $186,000 after purchasing an additional 3,399 shares in the last quarter. Advisors Preferred LLC purchased a new position in Grifols during the first quarter worth about $368,000. Vident Advisory LLC lifted its position in Grifols by 134.5% during the first quarter. Vident Advisory LLC now owns 69,564 shares of the biotechnology company’s stock worth $495,000 after buying an additional 39,902 shares during the period. Groupe la Francaise purchased a new position in Grifols during the first quarter worth about $1,699,000. Finally, Cetera Investment Advisers lifted its position in Grifols by 16.1% during the first quarter. Cetera Investment Advisers now owns 35,254 shares of the biotechnology company’s stock worth $251,000 after buying an additional 4,900 shares during the period.

Grifols Company Profile

Grifols, SA operates as a plasma therapeutic company in Spain, the United States, Canada, and internationally. The company provides immunoglobulin to treat immunodeficiencies; albumin used to restore circulatory volume and protein loss in pathophysiological conditions, such as liver cirrhosis, cardiocirculatory failure, trauma and severe burns; alpha-1 proteinase inhibitor, a plasma protein, used to treat a genetic disease known as alpha-1; factorVIII/von Willerbrand factor and factor IX, clotting factors for the treatment of hemophilia A and von Willebrand’s disease, as well as hemophilia B; antithrombin III to treat hereditary antithrombin deficiency; Fostamatinib, a spleen tyrosine kinase inhibitor; combination of fibrinogen and enzyme thrombin that acts as a biological sealant to control surgical bleeding; and plasma exchange with albumin used to treat Alzheimer’s disease.